Isatuximab for Stem Cell Transplant-Ineligible Multiple Myeloma: An Editorial

The recent approval of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) marks a significant advancement in the treatment of stem cell transplant-ineligible multiple myeloma (MM) patients. MM, the second most common hematological malignancy globally, poses substantial challenges, especially for patients who are unable to undergo autologous stem cell transplantation due to advanced age or comorbidities. Isatuximab, a CD38-targeting monoclonal antibody, has demonstrated promising efficacy in the pivotal trial, which reported a 40% reduction in disease progression or death for patients treated with Isa-VRd compared to bortezomib-lenalidomide-dexamethasone alone. The trial also showed higher rates of complete response and minimal residual disease (MRD)-negative status in the Isa-VRd group without introducing new safety concerns. These findings suggest that isatuximab's integration into first-line therapy could substantially improve long-term outcomes for this underserved patient population. Clinicians are encouraged to adopt regular MRD monitoring and provide comprehensive patient education on potential side effects to optimize treatment adherence. Further research on isatuximab's use in combination with other emerging therapies may continue to expand therapeutic possibilities, offering hope for more effective management of MM.